ImmunityBio, Inc.
IBRX
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Pā¦ read more
Healthcare
Biotechnology
9 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.55
Price-5.91%
-$0.16
1Y
Price
Market Cap
$2.410b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-226602.5%
EBITDA Margin-335272.5%
Net Profit Margin-270615.0%
Free Cash Flow MarginRevenue
$56.600m
-51.5%
1y CAGR+11.1%
3y CAGR+22.0%
5y CAGREarnings
-$367.092m
-3.0%
1y CAGR-20.7%
3y CAGR-29.5%
5y CAGREPS
-$0.48
+7.8%
1y CAGR-6.1%
3y CAGR-17.7%
5y CAGRBook Value
-$569.819m
$402.076m
Assets$971.895m
Liabilities$535.316m
DebtDebt to Assets
133.1%
-2.6x
Debt to EBITDAFree Cash Flow
-$356.663m
-3.9%
1y CAGR-12.2%
3y CAGR-28.6%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company